In a large, federally-funded trial investigating niacin (vitamin B-3), researchers hoping to harness its known ability to raise HDL, or “good cholesterol,” levels to prevent heart disease were once again disappointed. After niacin was administered to patients in conjunction with cholesterol-lowering statin medications, the study was halted 18 months prematurely, due to patients' increased risk for cardiovascular events.
In a large, federally-funded trial investigating niacin (vitamin B-3), researchers hoping to harness its known ability to raise HDL, or “good cholesterol,” levels to prevent heart disease were once again disappointed. After niacin was administered to patients in conjunction with cholesterol-lowering statin medications, the study was halted 18 months prematurely, due to patients' increased risk for cardiovascular events.